icon
icon
Overview

Conjunctival tumours are abnormal growths that develop on the conjunctiva, the thin membrane covering the white of the eye and lining the eyelids. They may arise from epithelial cells, melanocytes, lymphoid tissue, blood vessels, nerves, or other structures.

Early assessment is important because benign and malignant conjunctival lesions can appear similar. At Apollo Cancer Centres, conjunctival tumours are assessed by a multidisciplinary team that may include ocular oncologists, corneal and ophthalmic surgeons, medical oncologists, haemato-oncologists, radiation oncologists, pathologists, radiologists, genetic counsellors, and ocular reconstruction specialists.

Risk Factors for Conjunctival Tumours

Risk factors vary according to the tumour type and may include:
Ultraviolet Exposure

Ultraviolet Exposure

Long-term sunlight exposure is associated with ocular surface squamous neoplasia and may contribute to conjunctival melanoma risk.
Fair Skin and Light Pigmentation

Fair Skin and Light Pigmentation

These may increase the risk of melanocytic conjunctival tumours.
Primary Acquired Melanosis With Atypia

Primary Acquired Melanosis With Atypia

This is an important precursor of some conjunctival melanomas.
Conjunctival Naevus

Conjunctival Naevus

A small proportion of conjunctival melanomas arise from a pre-existing naevus.
Human Papillomavirus

Human Papillomavirus

HPV may be associated with some conjunctival papillomas and ocular surface squamous neoplasias, although not every tumour is HPV-related.
HIV Infection Or Immune Suppression

HIV Infection or Immune Suppression

Reduced immune function increases the risk of ocular surface squamous neoplasia and certain lymphomas.
Xeroderma Pigmentosum

Xeroderma Pigmentosum

This inherited condition causes extreme sensitivity to ultraviolet radiation and increases ocular-surface cancer risk.
Increasing Age

Increasing Age

Several malignant conjunctival tumours are more common in older adults, although they may occur at any age.
Previous Skin Or Eye Cancer

Previous Skin or Eye Cancer

A personal history of melanoma or other cancers may influence risk assessment.
Chronic Ocular-Surface Damage

Chronic Ocular-Surface Damage

Persistent inflammation or scarring may be relevant in selected squamous tumours.
Lymphoid Or Immune Conditions

Lymphoid or Immune Conditions

Autoimmune disease, immune suppression, or previous lymphoma may be associated with conjunctival lymphoma.
Most people with a conjunctival tumour do not have an identifiable inherited condition or preventable cause.

Conjunctival Tumour Signs and Symptoms

Possible signs and symptoms include:

A new growth, spot, lump, or thickened area on the surface of the eye

A lesion that gradually increases in size

A new brown, black, pink, red, white, or yellow area on the conjunctiva

Change in the size, colour, thickness, or blood-vessel pattern of an existing pigmented spot

A raised, gelatinous, fleshy, scaly, or wart-like lesion

A persistent white plaque near the edge of the cornea

Prominent or irregular blood vessels feeding a lesion

A painless salmon-pink patch, which may occur with conjunctival lymphoma

Persistent redness or irritation that affects one area

A foreign-body sensation

Excessive tearing

Recurrent bleeding from the lesion

Blurred vision if the lesion extends onto the cornea

Reduced eye movement, a protruding eye, pain, or vision loss in advanced disease

A lump near the ear or in the neck if regional lymph nodes are involved

Many conjunctival lesions are benign. However, any growing, changing, unusually vascular, or newly pigmented lesion should be examined by an ophthalmologist.

How Conjunctival Tumours Are Diagnosed

Diagnosis begins with a review of symptoms, lesion duration and growth, previous photographs, ultraviolet exposure, immune status, previous cancers, and personal or family history of melanoma. The ophthalmologist examines the entire conjunctiva, including the areas beneath the eyelids, because some tumours are multifocal or extend beyond the visible lesion.

• • •

Slit-Lamp Examination

Slit-lamp examination provides a magnified view of the conjunctiva and cornea.

The specialist assesses:

  • Location and size

  • Colour and pigmentation

  • Thickness and surface appearance

  • Cysts, keratin, or ulceration

  • Tumour blood vessels

  • Corneal involvement

  • Mobility over underlying tissue

  • Extension beneath the eyelids

  • Features suggesting invasion

Eyelid Eversion

The upper and lower eyelids may be turned outward to examine the palpebral and forniceal conjunctiva. This helps identify hidden or multifocal disease.

Clinical Photography

High-resolution photographs document the tumour's appearance and dimensions. Serial images help determine whether an observed lesion is changing.

Anterior-Segment Optical Coherence Tomography

High-resolution anterior-segment OCT provides cross-sectional images of the conjunctival and corneal epithelium.

It may help:

  • Identify epithelial thickening

  • Define the edge of ocular surface squamous neoplasia

  • Distinguish some epithelial lesions from deeper tumours

  • Monitor response to topical treatment

OCT can support diagnosis but does not replace biopsy when histological confirmation is required.

Ultrasound Biomicroscopy

Ultrasound biomicroscopy assesses the depth of a conjunctival tumour and may identify involvement of the sclera, ciliary body, or internal eye structures.

MRI

MRI of the orbits may be performed when:

  • A tumour appears deeply invasive

  • Orbital extension is suspected

  • Eye movement is restricted

  • Conjunctival lymphoma extends beyond the visible surface

  • Surgical or radiation planning requires further anatomical detail

CT Scan

CT may be used to assess orbital bone, regional lymph nodes, or systemic disease. It may also be useful when MRI is unsuitable.

PET-CT

PET-CT may be considered for:

  • Conjunctival lymphoma

  • Advanced conjunctival melanoma

  • Suspicious lymph nodes

  • Possible distant metastases

  • A conjunctival lesion suspected to be a metastasis from another cancer

Small or superficial eye lesions may not be reliably detected on PET-CT.

Excisional Biopsy

A small, localised suspicious lesion may be removed completely for diagnosis. For suspected squamous neoplasia or melanoma, a carefully planned no-touch technique is used to minimise direct handling of the tumour. Cryotherapy may be applied to the conjunctival margins.

Incisional Biopsy

A representative portion of a large or diffuse lesion may be removed when complete excision would cause unnecessary damage or when the diagnosis will determine non-surgical treatment. Incisional biopsy is commonly appropriate for suspected conjunctival lymphoma.

Mapping Biopsies

Multiple small biopsies may be used to determine the extent of diffuse or multifocal disease, particularly primary acquired melanosis with atypia or widespread epithelial neoplasia.

Lymph-Node Biopsy

A suspicious lymph node near the ear, jaw, or neck may undergo ultrasound-guided biopsy. This can confirm regional spread and influence treatment.

Sentinel Lymph-Node Biopsy

Sentinel lymph-node biopsy may be considered for selected patients with higher-risk conjunctival melanoma. It is not routinely required for every tumour.

Laboratory

The biopsy tissue is examined by a specialist ocular pathologist.

Assessment may include:

  • Histopathology: Determines whether the lesion is benign, pre-invasive, or malignant and identifies its cell of origin.

  • Margin assessment: Establishes whether abnormal cells reach the edge of the removed tissue.

  • Invasion assessment: Determines whether the tumour remains within the conjunctival epithelium or has entered the stroma, sclera, cornea, eye, eyelid, or orbit.

  • Squamous markers: Immunohistochemistry may help confirm squamous differentiation and exclude another tumour type.

  • Melanocytic markers: SOX10, S100, Melan-A, HMB-45, and other markers may support a diagnosis of conjunctival melanoma.

  • Lymphoma typing: Immunohistochemistry and flow cytometry may identify the lymphoid cell type and distinguish reactive inflammation from lymphoma.

  • Molecular testing: Selected conjunctival melanomas may undergo testing for BRAF, NRAS, KIT, NF1, or other alterations that could influence treatment in advanced disease.

  • Proliferation assessment: Mitotic activity and Ki-67 may provide information about tumour behaviour.

  • HPV-related testing: May be performed in selected papillomas or squamous lesions when clinically relevant.

  • Systemic lymphoma tests: Blood counts, blood chemistry, bone-marrow assessment, or other tests may be performed when conjunctival lymphoma is diagnosed.

  • Treatment-planning tests: Kidney, liver, thyroid, and other laboratory assessments may be required before systemic therapy.

No routine blood tumour marker can diagnose a conjunctival tumour. Laboratory testing is selected according to the pathological type.

Staging of Conjunctival Tumours

Benign conjunctival tumours are not staged. Malignant tumours are staged according to their specific pathology.

For Ocular Surface Squamous Neoplasia, staging considers:

  • Tumour size and location

  • Corneal involvement

  • Invasion into the sclera, eyelid, eye, or orbit

  • Regional lymph-node involvement

  • Distant metastases

For Conjunctival Melanoma, staging considers:

  • Site and extent across the conjunctiva

  • Tumour thickness

  • Invasion of the eyelid, sclera, eye, orbit, or surrounding structures

  • Regional lymph-node involvement

  • Distant metastases

Conjunctival lymphoma is assessed according to:

  • One or both eyes being involved

  • Extent within the ocular adnexa

  • Regional lymph nodes

  • Bone marrow or organ involvement

  • Lymphoma subtype

Systemic staging determines whether the disease is localised to the eye or part of more widespread lymphoma.

Conjunctival Tumours Conjunctival Tumours

How Conjunctival Tumours Are Treated

• •

No-Touch Excision

Suspected conjunctival melanoma or localised ocular surface squamous neoplasia may be removed using a no-touch technique. The surgeon avoids grasping or cutting directly through the tumour. Cryotherapy may be applied to the conjunctival margins to destroy microscopic residual cells.

Corneal And Scleral Treatment

When a lesion extends onto the cornea, the involved surface epithelium may be removed. Partial-thickness scleral removal may be required if deeper invasion is suspected.

Surgery For Conjunctival Melanoma

Treatment may involve wide local excision with margin cryotherapy. Additional topical or radiation treatment may be recommended according to the tumour's extent and margin status. Regional lymph nodes are assessed clinically and through imaging or biopsy when indicated.

Enucleation Or Orbital Exenteration

Removal of the eye or orbital contents is rarely required. It may be considered when an aggressive tumour has extensively invaded the eye or orbit and cannot be controlled using more conservative treatment.

Topical Chemotherapy

Topical treatment may be used for ocular surface squamous neoplasia as primary or additional therapy.

Medicines may include:

  • Mitomycin C

  • 5-fluorouracil

  • Interferon alfa-2b where available

Treatment can cover the entire ocular surface, which may be useful for diffuse or multifocal disease. Side effects may include redness, irritation, tearing, corneal injury, or limbal stem-cell damage.

Topical Treatment For Melanocytic Disease

Topical mitomycin C may be considered for selected intraepithelial melanocytic disease or residual primary acquired melanosis with atypia. It is not an adequate treatment for invasive conjunctival melanoma by itself.

Lymphoma Treatment

Localised conjunctival lymphoma is often treated with low-dose or standard-dose radiation according to the lymphoma subtype and extent.

Systemic or bilateral disease may require:

  • Anti-CD20 antibody therapy

  • Immunochemotherapy

  • Other lymphoma-directed treatment

  • Observation in selected indolent cases

  • Antibiotic treatment only in carefully selected infection-associated cases

Management is planned with a hemato-oncology team

Treatment For Advanced Conjunctival Melanoma

Unresectable or metastatic conjunctival melanoma may be treated using systemic approaches similar to those used for mucosal or cutaneous melanoma, depending on tumour biology.

Options may include:

  • Immune-checkpoint inhibitors

  • BRAF- and MEK-directed treatment for eligible BRAF-mutated tumours

  • KIT-directed treatment for selected KIT-altered cancers

  • Other molecularly targeted therapy

  • Clinical trials

Conjunctival melanoma is biologically different from uveal melanoma and should not automatically follow the same systemic treatment pathway.

Plaque Brachytherapy

A radioactive plaque may be placed temporarily over a selected tumour bed to treat residual or deeply invasive disease while limiting radiation to surrounding tissues. It may be considered after excision of selected conjunctival melanomas or squamous cancers.

External Beam Radiation Therapy

External radiation may be used for:

  • Conjunctival lymphoma

  • Positive or unresectable margins

  • Invasive squamous cell carcinoma

  • Conjunctival melanoma involving deeper tissues

  • Regional lymph-node disease

  • Orbital extension

  • Recurrent disease

Proton Therapy

Proton therapy may be considered for selected extensive, recurrent, or deeply invasive tumours when reducing radiation exposure to surrounding ocular and orbital structures could provide an advantage.

Radiation For Metastatic Disease

Radiation may be used to control painful bone lesions, brain metastases, regional lymph nodes, or other symptom-producing disease.

Prognosis-for-Conjunctival-Tumours
Prognosis for Conjunctival Tumours

The outlook depends on the tumour type. Benign lesions generally have an excellent prognosis. Ocular surface squamous neoplasia is often highly treatable but can recur, particularly when margins are involved or immune suppression continues.

Conjunctival melanoma has a greater risk of local recurrence, regional lymph-node spread, and distant metastasis. Conjunctival lymphoma is often indolent, but prognosis depends on subtype and systemic involvement.

Factors influencing prognosis include:
Pathological type
Tumour size, thickness, and location
Complete removal and margin status
Depth of invasion
Multifocal disease
Local recurrence
Regional lymph-node involvement
Distant metastases
Immune status
Molecular findings
Lymphoma subtype and systemic extent

Long-term follow-up is important because some conjunctival malignancies can recur years after treatment.

Why Choose ACC for Conjunctival Tumour Treatment

Multidisciplinary care involving ocular oncology, corneal surgery, medical oncology, haemato-oncology, radiation oncology, pathology, and reconstruction

Detailed slit-lamp examination with eyelid eversion and clinical photography

Anterior-segment OCT, ultrasound biomicroscopy, MRI, CT, and PET-CT when appropriate

Specialist biopsy planning for small, large, diffuse, or multifocal lesions

No-touch excision with margin cryotherapy for selected tumours

Specialist ocular pathology with margin, invasion, and molecular assessment

Topical chemotherapy for appropriately selected ocular surface squamous neoplasia

Plaque brachytherapy, external radiation, and proton therapy assessment

Systemic staging and lymphoma-directed treatment for conjunctival lymphoma

Immunotherapy and biomarker-directed treatment for selected advanced conjunctival melanoma

Amniotic membrane and other ocular-surface reconstruction

Regional lymph-node assessment and surveillance

Long-term monitoring for recurrence, treatment effects, and distant spread
Frequently Asked Questions
01 Are all conjunctival tumours cancerous?
icon icon
No. Many are benign, including most conjunctival naevi, cysts, dermoids, and papillomas. Examination and sometimes biopsy are needed to determine the tumour type.
02 What changes in an eye spot should be evaluated?
icon icon
Growth, colour change, thickening, new blood vessels, bleeding, loss of previously visible cysts, corneal extension, or persistent irritation should be assessed.
03 What is ocular surface squamous neoplasia?
icon icon
It is a spectrum of abnormal squamous-cell growth ranging from epithelial dysplasia and carcinoma in situ to invasive squamous cell carcinoma.
04 Is primary acquired melanosis cancer?
icon icon
Not always. It is an area of acquired conjunctival pigmentation. Lesions containing atypical melanocytes can increase the risk of conjunctival melanoma and require specialist assessment.
05 Is conjunctival melanoma the same as uveal melanoma?
icon icon
No. Conjunctival melanoma develops on the eye surface and is biologically closer to cutaneous or mucosal melanoma. Uveal melanoma develops inside the eye and follows a different disease pathway.
06 Is biopsy always necessary?
icon icon
No. A clearly benign lesion may be observed. A growing, atypical, invasive, or otherwise suspicious lesion generally requires biopsy for diagnosis.
07 Can a conjunctival tumour be removed without removing the eye?
icon icon
Yes. Most are managed with local excision, cryotherapy, topical treatment, or focused radiation. Removal of the eye or orbit is reserved for extensive invasive disease.
08 Can eye drops treat conjunctival cancer?
icon icon
Selected topical medicines can treat ocular surface squamous neoplasia and some intraepithelial melanocytic disease. They are not suitable for every tumour and do not replace surgery for deeply invasive cancer.
09 What does a salmon-pink patch on the eye mean?
icon icon
A salmon-pink conjunctival lesion can occur with lymphoma, although other conditions may look similar. Biopsy is required to establish the diagnosis.
10 Can conjunctival melanoma spread?
icon icon
Yes. It may spread to lymph nodes near the ear, jaw, or neck and later to distant organs. Long-term local, regional, and systemic surveillance is important.
11 Can conjunctival tumours return after treatment?
icon icon
Yes. Squamous neoplasia, melanoma, papilloma, and lymphoma can recur. Follow-up includes examination of the entire conjunctiva and any relevant regional or systemic assessment.
12 Can sunlight protection prevent conjunctival cancer?
icon icon
Ultraviolet protection may reduce ocular-surface exposure but cannot prevent every conjunctival tumour. Wraparound sunglasses and a broad-brimmed hat are reasonable protective measures.
image image
Book an Appointment
Please Enter Your Name
Please Enter Your Mobile Number
Please Enter OTP